UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
ANACOR PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $0.001 Par Value
(Title of Class of Securities)
032420 101
(CUSIP Number)
Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February 14, 2012
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 2 of 7 |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) GlaxoSmithKline plc |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o (b) o |
| 3 | SEC USE ONLY |
| 4 | SOURCE OF FUNDS WC |
| 5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o |
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 2,771,374 |
| 8 | SHARED VOTING POWER -0- |
| 9 | SOLE DISPOSITIVE POWER 2,771,374 |
| 10 | SHARED DISPOSITIVE POWER -0- |
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,771,374 shares of Common Stock (1) |
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o |
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 7.8% of the shares of Common Stock (2) |
| 14 | TYPE OF REPORTING PERSON CO |
Footnotes:
(1) Shares held of record by GlaxoSmithKline LLC f/k/a SmithKline Beecham Corporation, a wholly owned subsidiary of the Reporting Person, issued as of November 30, 2010.
(2) Based on 35,568,645 shares of Common Stock as of November 30, 2012.
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 3 of 7 |
This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (the “Original Schedule 13D”) with respect to the shares of common stock, par value $0.001 per share (the “Common Stock”), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.
Item 2. Identity and Background.
The response set forth in Item 2 of the Original Schedule 13D is hereby amended by deleting Schedule 1 in its entirety, and replacing it with Schedule 1 attached hereto.
Item 5. Interest in Securities of the Issuer.
The response set forth in the first paragraph of Item 5 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
(a) GlaxoSmithKline plc beneficially owns 2,771,374 shares of Common Stock, issued as of November 30, 2010, which represents 7.8% of the 35,568,645 shares of Common Stock outstanding as of November 30, 2012. The Issuer issued an additional 3,250,000 shares of Common Stock on February 14, 2012 and 4,000,000 shares of Common Stock on October 23, 2012.
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 4 of 7 |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
| | GLAXOSMITHKLINE PLC |
| | |
| | /s/ Victoria A. Whyte |
| | By: Victoria A. Whyte |
| | Title: Company Secretary |
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 5 of 7 |
SCHEDULE I
| | | | Principal Occupation or Employment | | |
| | | | | | | |
| Board of Directors | | | | | | |
| | | | | | | |
| Sir Andrew Witty | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Chief Executive Officer | | British |
| | | | | | | |
| Simon Dingemans | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Chief Financial Officer | | British |
| | | | | | | |
| Dr. Moncef Slaoui | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Executive Director Chairman Global Research & Development and Vaccines | | |
| | | | | | | |
| Sir Christopher Gent | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Chairman and Company Director | | British |
| | | | | | | |
| Professor Sir Roy Anderson | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | British |
| | | | | | | |
| Dr. Stephanie Burns | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | US |
| | | | | | | |
| Stacey Cartwright | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | British |
| | | | | | | |
| Sir Crispin Davis | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | British |
| | | | | | | |
| Judy Lewent | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | US |
| | | | | | | |
| Sir Deryck Maughan | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | British |
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 6 of 7 |
| | | | Principal Occupation or Employment | | |
| |
| Dr. Daniel Podolsky | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | US |
| | | | | | | |
| Tom de Swaan | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | Dutch |
| | | | | | | |
| Sir Robert Wilson | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | British |
| | | | | | | |
| Lynn Elsenhans | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | US |
| | | | | | | |
| Jing Ulrich | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | US |
| | | | | | | |
| Hans Wijers* | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Company Director | | Dutch |
| | | | | |
| *Appointment with effect from 1 April 2013 | | | | |
| | | | | | | |
| | | | | | | |
| Corporate Executive Team | | | | | | |
| | | | | | | |
| Sir Andrew Witty | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Chief Executive Officer | | British |
| | | | | | | |
| Simon Dingemans | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Executive Director and Chief Financial Officer | | British |
| | | | | | | |
| Dr. Moncef Slaoui | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Executive Director Chairman Global Research & Development and Vaccines | | |
| | | | | | | |
| Simon Bicknell | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Senior Vice President, Governance, Ethics and Assurance | | British |
| | | | | | | |
| Deirdre Connelly | | 1600 Vine Street, Philadelphia, PA 19102 | | President, North America Pharmaceuticals | | US |
CUSIP No. 032420 101 | SCHEDULE 13D/A | Page 7 of 7 |
| | | | Principal Occupation or Employment | | |
| |
Marc Dunoyer | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Head of Rare Diseases Unit and Chairman of GlaxoSmithKline Japan | | French |
| | | | | | | |
| Abbas Hussain | | 150 Beach Road 22-00 Gateway West 189720 Singapore | | President, Europe & Emerging Markets & Asia Pacific | | British |
| | | | | | | |
| William Louv | | Five Moore Drive PO Box 13398 Research Triangle Park North Carolina 27709 | | Senior Vice President, Core Business Services & Chief Information Officer | | US |
| | | | | | | |
| David Redfern | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Chief Strategy Officer | | British |
| | | | | | | |
| Christophe Weber | | Avenue Fleming, 20 B-1300 Wavre Belgium | | President, Vaccines | | French |
| | | | | | | |
| Claire Thomas | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Senior Vice President, Human Resources | | British |
| | | | | | | |
| Philip Thomson | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | Senior Vice President, Global Communications | | British |
| | | | | | | |
| Daniel Troy | | One Franklin Plaza Philadelphia, PA 19102 | | Senior Vice President & General Counsel | | US |
| | | | | | | |
| Dr. Patrick Vallance | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | President, Pharmaceuticals R&D | | British |
| | | | | | | |
| Emma Walmsley | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | President, Consumer Healthcare Worldwide | | British |
| | | | | | | |
| Roger Connor | | 980 Great West Road Brentford Middlesex, England TW8 9GS | | President, Global Manufacturing & Supply | | British |
